What is it about?
Tuberculosis (TB) is a major global health issue, especially with the rise of drug-resistant strains. Researchers are exploring new treatments, including lansoprazole sulfide (LPZS), a metabolite of lansoprazole (a stomach acid reducer), as a potential TB drug. They studied how LPZS works by examining its interaction with a key enzyme complex in the respiratory chain of a TB-related bacterium. They found that LPZS binds to a specific part of the enzyme, blocking its function and stopping the bacteria from producing energy. This detailed study helps understand how LPZS can fight TB and how bacteria might develop resistance to it, guiding future drug development.
Featured Image
Photo by National Institute of Allergy and Infectious Diseases on Unsplash
Read the Original
This page is a summary of: Inhibition mechanism of potential antituberculosis compound lansoprazole sulfide, Proceedings of the National Academy of Sciences, November 2024, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2412780121.
You can read the full text:
Contributors
The following have contributed to this page
